Edison Pharmaceuticals Lands Series E
Mountain View-based Edison Pharmaceuticals, a developer of treatments for inherited mitochondrial diseases and other rare and neglected diseases, said today that it has raised a Series E preferred financing round. Financial details of the funding, and source of funds, were not disclosed. The firm said the funding will go towards US and European trials of its clinical candidates. A recent regulatory filing from the firm indicates the company recently raised around $4.0M in funding.
posted on Tuesday, September 13, 2011 (Link to more information)
Related companies:
Edison Agrosciences, Inc.
Related stories:
> Edison Pharmaceuticals Nabs $20M To Treat Mitochondrial Disease
> Edison Software Acquires Business From Return Path
> Aldea Pharmaceuticals Takes $24M
> Portola Pharmaceuticals Lands $60M
> Bridge Pharmaceuticals Raises $35M
silicontap.com Home